We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.00 | -0.33% | 1,813.00 | 1,810.00 | 1,811.00 | 1,838.00 | 1,804.00 | 1,818.00 | 365,955 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.85 | 4B |
Date | Subject | Author | Discuss |
---|---|---|---|
28/7/2016 15:15 | Boring share. | r ball | |
26/7/2016 13:32 | This just seems to be going up which is nice so assume that the take over going well and seems to have good news flow but of course some stage will go down question is when | mrthomas | |
22/7/2016 14:31 | ah...the trend is your friend as they say...until it breaks. | r ball | |
22/7/2016 13:31 | Fair enough. I read an article in the Motley Fool saying weak GBP benefits Hikma. It really doesn't, apart from the FX translation (as GBP drops, it looks cheaper in USD terms). Dangerous levels here - so much priced in and stock grinding higher on ever-decreasing volumes. | rrb | |
22/7/2016 13:20 | Sorry. meant GBP hedge. as £ drops share price rises. | r ball | |
22/7/2016 11:57 | how can a company earning in USD with a large cost base in USD and reporting in USD be a USD hedge?! | rrb | |
21/7/2016 07:31 | Gets better. Fwiw. Look at fx effect on halma | r ball | |
20/7/2016 19:09 | I'm alone here. | r ball | |
15/7/2016 18:37 | Inverse relationship to nos of posts | r ball | |
15/7/2016 10:12 | and that as well looking to keep this a a long term hold if possible but am surprised at how little following has | mrthomas | |
06/7/2016 18:26 | Agree these are doing very well and saw a report from a good broker saying they impressed with the company and see more upside which is good | mrthomas | |
01/7/2016 15:54 | staggeringly few comments. | r ball | |
01/7/2016 11:52 | They entered the FTSE 100 on 20 June. Fund buying to adjust weightings. | broadwood | |
01/7/2016 11:46 | there is a lot m ore to go here. Watch sector rotation from property into pharma. also watch for more business friendly climate. PPI deadline (coming), Living wage (abandoned) etc. | r ball | |
01/7/2016 10:51 | could be Middle East factor but done very well on this share in past 4 months see your logic re ex rate $ taking to higher at least will keep it in Top 100 | mrthomas | |
30/6/2016 21:59 | £28 target (well £25 using last weeks $ krona rate) | r ball | |
30/6/2016 18:47 | why is this share so overlooked?? | r ball | |
28/6/2016 18:35 | Its a $ hedge with a stable income stream. Expecting it to be up 15% in current market. More upside to come. More to go. | r ball | |
28/6/2016 13:37 | Be surprised how well doing was thinking of selling as done very well on this stock in 4 months | mrthomas | |
28/6/2016 11:38 | safe haven. $ denominated earnings. | r ball | |
06/6/2016 15:18 | Jordanian drugs-maker Hikma became the fourth pharma constituent of the FTSE 100 in March 2015, before falling out of favour with investors and dropping out of the top index a year later. But a recent positive trading statement has seen the share price rally enormously and last month the group rejoined the FTSE 100 having replaced satellite firm Insmarsat. | broadwood | |
02/6/2016 19:35 | quite. hold.ps; ftse up 0.8% in past 12 months. if you beat this you are doing very very well | r ball | |
02/6/2016 07:32 | Should keep bubbling along as Fund Managers up their weightings. Hikma Pharmaceuticals is set to enter the FTSE 100 index as satellite firm Inmarsat drops to the FTSE 250. The changes will take effect on June 20, London Stock Exchange said today. Hikma Pharmaceuticals's promotion to Britain's blue chip index comes after its shares surged 45 per cent since mid-March. The company expects its full year group revenue to be between $2bn (£1.3bn) and $2.1bn (£1.4bn | broadwood |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions